J. Neidhart, A. Staubus, D. Young
Mar 1, 1978
Citations
0
Influential Citations
0
Citations
Journal
Cancer treatment reports
Abstract
Cytembena is a nonmyelosuppressive drug that has received phase I--II trials in this country and is presently being used as a chemotherapeutic agent in Europe. Sterile abscesses at the site of im injection and "autonomic storm" after iv bolus represent the most frequent dose-limiting toxic effects, and intermittent schedules reflect reports of prolonged plasma levels of drug. This report of excellent oral absorption and a short half-life suggests that alternative routes and schedules of administration should be evaluated. The dose-limiting toxic effects observed after frequent oral administration were transient proteinuria and increased creatinine levels.